Argon AI vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 41)
Argon AI logo

Argon AI

EmergingHealthcare

General

San Francisco pharma AI assistant with natural language search across clinical and commercial data; $11.5M Crosslink seed serving two top-15 global pharma companies with 1,000+ biopharma company waitlist.

AI VisibilityBeta
Overall Score
C41
Category Rank
#356 of 596
AI Consensus
67%
Trend
stable
Per Platform
ChatGPT
46
Perplexity
37
Gemini
36

About

Argon AI is a San Francisco-based enterprise AI company building AI-powered intelligence assistants for pharmaceutical and life sciences companies — enabling natural language search, cross-data analysis, and automated intelligence synthesis across clinical, commercial, and external data sources that pharmaceutical researchers and commercial teams need for competitive intelligence, market research, and drug development decisions. Founded in 2023 and backed with $11.5 million raised including a $5.5 million seed round led by Crosslink Capital and Wireframe Ventures, Argon AI serves two top-15 global pharmaceutical companies with firm-wide deployments and maintains a waitlist of 1,000+ biopharma companies.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

41
Overall Score
90
#356
Category Rank
#2
67
AI Consensus
83
stable
Trend
stable
46
ChatGPT
92
37
Perplexity
93
36
Gemini
89
37
Claude
96
47
Grok
95

Key Details

Category
General
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.